文摘
摘要目的:描述和比较PET-based分子病理学和特定领域的认知能力之间的关系在早发性(EOAD、年龄< 65)与晚发性阿尔茨海默氏症(负载,年龄≥65岁)。
背景:τ,淀粉样蛋白和神经退行性变的有不同的关联广告的认知。这些联系EOAD和负载之间可能有所不同。
设计/方法:Amyloid-positive参与者患有轻度认知障碍或AD痴呆(EOAD n = 60岁,平均年龄58±4、MMSE 21±6中,58%的女性;负载n = 53岁,平均年龄74±MMSE 23±5, 45%女性)接受18F-flortaucipir (FTP-PET,τ,n = 113),11C-PIB-PET (PIB-PET amyloid-βn = 113)、和18F-fluorodeoxyglucose-PET(正,葡萄糖代谢,n = 84)。综合得分为情景记忆、语义记忆、语言、执行功能和视觉空间域的计算基于神经心理测试。Voxelwise回归评估宠物模式和认知能力之间的相关性在每个年龄段和总样本,包括宠物x年龄组交互模型中(在未修正的阈值p < 0.001 voxel-level FWE p < 0.05集群级别)。中介分析估计的直接和间接(正介导)FTP-PET和认知能力之间的联系感兴趣的。
结果:EOAD FTP-PET绑定在顶叶,较高侧颞,和外侧额叶皮质;更严重的正代谢减退楔前叶和角形脑回;和更大的PIB-PET绑定在枕叶相比,负载。FTP-PET和摄影,但不是PIB-PET,明显与预期特定领域的认知模式在两个年龄组(如perisylvian /语言,额/执行,枕/视觉空间的)。在整个队列,没有明显的年龄和宠物之间的交互模式。中介分析显示正介导FTP-PET和认知之间的关系在两个年龄组在所有领域除了负载情景记忆。在EOAD,额外的FTP-PET直接影响被观察到在语义记忆(p = 0.046)和语言(p = 0.02)。
结论:τ和神经退行性变的,但不是淀粉样蛋白,与认知有关EOAD和负载。τ与认知神经退化的独立大协会EOAD,建议加强τ神经毒性和/或少co-pathologies导致的症状。Anti-tau疗法可能会减缓认知能力的衰退EOAD和负载。
披露:坦纳博士没有披露。莱昂纳多Iaccarino没有披露。劳伦·爱德华兹没有披露。Renaud洛杉矶生活乐趣的机构收到NIH的研究支持。Renaud洛杉矶生活乐趣的机构已收到研究阿尔茨海默氏症协会的支持。阿米莉亚斯特罗姆没有披露。朱莉(Pham没有披露。泰勒悟道没有披露。Soleimani-Meigooni博士没有披露。Rosen博士没有披露。 The institution of Dr. Kramer has received research support from tau consortium. Dr. Kramer has received publishing royalties from a publication relating to health care. Dr. Miller has nothing to disclose. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axon Neurosciences. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GE Healthcare. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. The institution of Dr. Rabinovici has received research support from Avid Radiopharmaceuticals. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH.
